PacBio Posts 12-Cent Quarterly Loss as Turnaround Pressure Mounts
PACB has more than doubled off its 52-week low of $1.07.
Summary
PacBio reported a third-quarter loss of $37.8M, or 12 cents per share, on revenue of $40.6M. That lands after a rough stretch: Q2 revenue of $39.0M missed estimates in August, the company set its 2026 revenue outlook at $155M–$160M, and it pushed cash-flow breakeven further out. The new CEO, Mark Van Oene, is running a restructuring aimed at cutting $30M-$40M in annual costs, and the CFO has been selling shares under a pre-arranged 10b5-1 plan. With the stock at $2.57 and a market cap under $800M, the loss keeps the focus squarely on cash burn and whether the cost cuts land fast enough.
At the time of this announcement, PACB was trading at $2.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $792.6M. The 52-week trading range was $1.07 to $3.44. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.